Eli Lilly is a high-quality healthcare franchise with 56% revenue growth, a wide economic moat, and four consecutive double-digit earnings beats, but the stock has effectively reached the analyst consensus price target with only 0.9% headroom remaining — the setup favors accumulation on weakness rather than initiating at current levels.
Thesis pillars
- Wide Moat Margin Quality→Stable
- Consistent Earnings Outperformance→Stable
- Exceptional Revenue Growth Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Eli Lilly and Company (LLY) Stock Analysis
Temporary headwind edge
Healthcare · Drug Manufacturers - General
Wait for pullback to $1022.70. At $1126.50 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $1022.70 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.4): -0.5.
Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with cardiometabolic health products (including Mounjaro, Zepbound, and Jardiance) and oncology (Verzenio) anchoring a portfolio sold in approximately 90 countries. Six... Read more
Wait for pullback to $1022.70. At $1126.50 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $1022.70 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.4): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 2 days. Wait until post-earnings. Score 6.6/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news boost earnings 0.60, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 2d<=7d. Suitability: moderate.
About Eli Lilly and Company
About Eli Lilly and Company
Mounjaro and Zepbound, Eli Lilly's GLP-1/GIP-based incretin medicines for type 2 diabetes and obesity, together generated 56% of total revenues in 2025 — each individually exceeding $3 billion. Combined with Verzenio (breast cancer), Trulicity, Taltz, and Jardiance, the six highest-revenue products represented 82% of 2025 total revenues. Mounjaro and Zepbound carry U.S. compound patent protection through 2036, and products are sold in approximately 90 countries.
Eli Lilly sells prescription medicines through U.S. wholesale distributors — McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc. — each of which accounts for a significant percentage of consolidated revenue; no other single customer exceeds 10%. Net revenue reflects rebates and discounts negotiated with pharmacy benefit managers and health plans; access to anti-obesity medicines faces particular friction because self-insured U.S. employers must generally opt in for obesity coverage, and payers in many international markets do not cover weight-loss indications. A growing share of U.S. sales flows through LillyDirect, the company's direct-to-patient platform launched to reduce formulary dependency. Jardiance and Basaglar are co-developed with Boehringer Ingelheim, while Tyvyt is commercialized in China with Innovent Biologics.
Show full overview
The Inflation Reduction Act's negotiation mechanism targets Lilly's portfolio directly: HHS selected Jardiance as one of the first ten medicines subject to government-set Medicare prices effective 2026, then in January 2026 selected Trulicity and Verzenio with government pricing effective 2028. Trulicity also faces U.S. compound patent expiry and biologics data protection loss in 2027, concentrating erosion risk within a two-year window. The 10-K notes the company expects additional products selected in future years, which would accelerate revenue erosion further.
See also: Healthcare · Drug Manufacturers - General
From Eli Lilly and Company's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-04Recent Developments — Eli Lilly and Company
Latest news
- NEWS LLY: Lilly(Eli) & Co Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits — Stocktwits neutral
- NEWS LLY: Lilly(Eli) & Co Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com — stocktwits.com neutral
- NEWS Ahead of Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar — Morningstar neutral
- NEWS Why Is LLY Stock Rising Today? - stocktwits.com — stocktwits.com positive
- NEWS Eli Lilly Stock Could Rise Sharply After Earnings (NYSE:LLY) - Seeking Alpha — Seeking Alpha positive
Generated 2026-08-04T09:03:24Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $1022.70. At $1126.50 the A.R:R is 0.4:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $1022.70 (Ma200 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.4): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Earnings in 2 days. Wait until post-earnings. Target $1149.27 (+2.0%), stop $950.04 (−18.6%), A.R:R 0.4:1. Score 6.6/10, moderate confidence.
Take-profit target: $1149.27 (+2.5% upside). Target $1149.27 (+2.0%), stop $950.04 (−18.6%), A.R:R 0.4:1. Stop-loss: $950.04.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.4): -0.5; Expensive valuation.
Eli Lilly and Company trades at a P/E of 40.8 (forward 25.5). TrendMatrix value score: 3.4/10. Verdict: Buy (Wait for Entry).
38 analysts cover LLY with a consensus score of 4.1/5. Average price target: $1277.
What does Eli Lilly and Company do?Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with...
Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with cardiometabolic health products (including Mounjaro, Zepbound, and Jardiance) and oncology (Verzenio) anchoring a portfolio sold in approximately 90 countries. Six products each generated more than $3 billion in revenue in 2025, collectively representing 82% of total revenues, with GLP-1/GIP medicines Mounjaro and Zepbound alone at 56%.